COPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center
|
|
- Mariah Murphy
- 5 years ago
- Views:
Transcription
1 COPD UPDATE 2012 ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center
2 Definition of COPD COPD is a preventable and treatable disease with some significant extra pulmonary effects that may contribute to the severity in individual patients. Healthy Alveolus The airflow limitation is usually progressive associated with an abnormal inflammatory response of the lung to noxious particles or gases. COPD
3 Of the six leading causes of death in the United States, only COPD has been increasing steadily since Source: Jemal A. et al. JAMA
4 COPD Mortality by Gender, U.S., Number Deaths x Men Women
5 COPD Mortality Worldwide Ischaemic heart dis Cerebrovascular dis Lower resp infection Diarrhoeal disease Perinatal disorders COPD Tuberculosis Measles Road Traffic Accidents Lung Cancer 6th rd Stomach Cancer HIV Suicide Source: Murray & Lopez. Lancet 1997
6 Diagnosis of COPD SYMPTOMS cough sputum shortness of breath EXPOSURE TO RISK FACTORS tobacco occupation indoor/outdoor pollution è SPIROMETRY
7 Classification of COPD Severity by Spirometry (2008) Stage I: Mild FEV 1 /FVC < 0.70 FEV 1 > 80% predicted Stage II: Moderate FEV 1 /FVC < % < FEV 1 < 80% predicted Stage III: Severe FEV 1 /FVC < % < FEV 1 < 50% predicted Stage IV: Very Severe FEV 1 /FVC < 0.70 FEV 1 < 30% predicted or FEV 1 < 50% predicted plus chronic respiratory failure 6
8 ıbode Index FEV1 6MWD MMRC Dyspnea scale BMI Celli BR, NEJM 2004
9 Symptom variability in patients with severe COPD: a pan-european cross-sectional study ı
10 Symptom variability in patients with severe COPD: a pan-european cross-sectional ıstudy
11 Obstructive Pattern
12 GOALS of COPD MANAGEMENT Relieve symptoms Prevent disease progression Improve exercise tolerance Improve health status Prevent and treat complications Prevent and treat exacerbations Reduce mortality 01
13 Therapy at Each Stage of COPD I: Mild II: Moderate III: Severe IV: Very Severe FEV 1 /FVC < 70% FEV 1 /FVC < 70% FEV 1 /FVC < 70% 50% < FEV 1 < 80% predicted ı ı FEV 1 /FVC < 70% 30% < FEV 1 < 50% predicted ı FEV 1 < 30% predicted or FEV 1 < 50% predicted plus chronic respiratory failure FEV 1 > 80% predicted Active reduction of risk factor(s); influenza vaccination Add short-acting bronchodilator (when needed) Add regular treatment with one or more long-acting bronchodilators (when needed); Add rehabilitation Add inhaled glucocorticosteroids if repeated exacerbations Add long term oxygen if chronic respiratory failure. Consider surgical treatments
14 Early Therapy Improves Outcomes of Exacerbations of Chronic Obstructive Pulmonary Disease Wilkinson et al. AJRCCM 2004 Effect of early treatment on recovery of exacerbation symptoms
15 Severe acute exacerbations and mortality in patients with COPD Soler-Cataluña et al. THORAX 2005 Kaplan-Meier survival curves by severity of exacerbations in patients with COPD: (1) no acute exacerbations of COPD (2) patients with acute exacerbations of COPD requiring emergency service visits without admission (3) patients with acute exacerbations of COPD requiring one hospital admission; (4) patients with readmissions
16 COPD EXACERBATIONS An event in the natural course of the disease characterized by a change in the patient s baseline dyspnea, cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset, and may warrant a change in regular medication in a patient with underlying COPD.
17 COPD EXACERBATIONS- Precipitating factors Infections (respiratory and nonrespiratory) Exposure to respiratory irritants and air pollution Co-morbid diseases (CHF, PE, IHD, Pneumothorax)
18 Severe acute exacerbations and mortality in patients with COPD Soler-Cataluña et al. THORAX 2005 ı Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD group B, patients with 1 2 acute exacerbations of COPD requiring hospital management group C, patients with 3 acute exacerbations of COPD
19 COPD EXACERBATIONS-Management Inhaled BD Treatment Systemic steroids (PO vs IV) Usually 2 weeks course Oxygen supply- at the lowest level needed Antibiotics No extensive evaluation for the cause of the exacerbation if it responds to initial treatment.
20 AE-COPD: Etiology 25% viruses 26% bacteria 27% combination of the two 22% other causes
21 COPD EXACERBATIONS-Management Inhaled BD Treatment Systemic steroids (PO vs IV) Usually 2 weeks course Oxygen supply- at the lowest level needed Antibiotics No extensive evaluation for the cause of the exacerbation if it responds to initial treatment.
22 Treatment failure of AE-COPD Change antibiotics with good coverage against P. aureginosa. Exclude Cor Pulmonale or CHF by Echo. Exclude PE and Pneumothorax Add aminophylline Exclude GERD
23 Pneumothorax in COPD Patients COPD is the most common cause for secondary spontaneous pneumothorax ı Due to rupture bleb hyperinflation mechanical ventilation Always in the DD of COPD Exacerbation CT scan should be perform in difficult cases. Definite treatment: VATS -pleurodesis
24 Core Pulmonale in COPD Causes Chronic alveolar hypoxemia Lung hyperinflation Increase blood viscosity Physical findings are late signs Peripheral edema is poorly correlated with RHF Echo measures of PAP are often inaccurate and may over diagnose pulmonary hypertension. No evidence to Anticoagulation Very important prognostic factor with 2 years survival less than 50% if PAP >45mmHg.
25 Co-morbidity in COPD l Cardiovascular morbidity. l Muscle wasting. l Osteoporosis. l Metabolic syndrome.
26 CVD and COPD Univariate Multivariate adjusted for age, sex, race, smoking status, pack-years, diabetes mellitus, BMI, education level, hypertension, HDL-C, LDL- C, fibrinogen Johnston et al, Thorax 2008
27 Prevalence of CVD in COPD Odds ratio Arrhythmia Angina Acute Myocardial Infarction Congestive Heart Failure Stroke Pulmonary Embolism Other Cardiovascular Disease Curkendall et al, AEP 2006
28 Cachexia in COPD CHRONIC ILLNESS e.g. Chronic heart failure, Chronic obstructive pulmonary disease, Chronic kidney disease, Chronic infection & Sepsis, Cancer Anorexia Inflammation Insulin resistance Hypogonadism FAT LOSS MUSCLE WASTING Evans et al, Clin Nutr 2008
29 Body composition in COPD Percentage Source: Eclipse study
30 Clinical consequences of osteoporosis Acute and chronic pain Kyphosis Loss of height Loss of mobility Bulging abdomen, reflux and other GI symptoms Breathing difficulties Depression Loss of independence REDUCED QUALITY OF LIFE
31 Prevalence of osteoporosis in COPD Osteoporosis: Tscores male female no mild moderate severe Sin et al, Am J Med 2003
32 Co-morbidity and prognosis Time to first hospitalisation within 5 years Predict time to first hospitalisation within 5 yrs by modified GOLD category and the presence of no ( ), one ( ), two ( ) or three ( ) comorbid diseases (diabetes, hypertension or cardiovascular disease). Mannino et al, ERJ 2008
33 Co-morbidity and prognosis Death within 5 years Predict death within 5 yrs by modified GOLD category and the presence of no ( ), one ( ), two ( ) or three ( ) comorbid diseases (diabetes, hypertension or cardiovascular disease). Mannino et al, ERJ 2008
34 Disease network of COPD CV Muscle wasting
35 COPD management moving from reductionism to an integrated approach to define, identify, and treat the multiple organ involvement of this complex syndrome.
36 Treatment of stable COPD Smoking cessation. Drug medications. Vaccinations. Oxygen therapy. Rehabilitation. Nutrition. Surgery.
37 Treatment of stable COPD Smoking cessation. Drug medications. Vaccinations. Oxygen therapy. Rehabilitation. Nutrition. Surgery.
38 Long-acting anticholinergics Tiotropium bromide Duration of action of more than 24 hours Regular use improves lung function 1,2, symptoms and health status, 1,2 reduces exacerbations, 3,4 and improves the effectiveness of a pulmonary rehabilitation programe 5 A long-term study is currently evaluating the effect on tiotropium bromide in the rate of decline in lung function 6 Side-effects Urinary retention, dry mouth, constipation 1. Casaburi R. Eur Respir J 2002; 2. Vincken W et al. Eur Respir J 2002; 3. Niewoehner DE et al. Ann Intern Med 2005; 4. Dusser D. Eur Respir J 2006; 5. Casaburi R et al. Chest 2005; 6. Decramer M. COPD 2004
39 GOLD steps of management I Mild II Moderate III Severe IV Very severe FEV 1 /FVC <0.70 FEV 1 80% predicted FEV 1 /FVC < % FEV 1 <80% predicted Active reduction of risk factor(s); influenza vaccination Add short-acting bronchodilator (when needed) FEV 1 /FVC < % FEV 1 <50% predicted FEV 1 /FVC <0.70 FEV 1 <30% predicted or FEV 1 <50% predicted plus chronic respiratory failure Add regular treatment with one or more long-acting bronchodilators (when needed); Add rehabilitation Add inhaled glucocorticosteroids if repeated exacerbations GOLD guidelines. Add long-term oxygen if chronic respiratory failure Consider surgical treatments
40 Combination ICS/bronchodilator therapy - Triple therapy ıbackground An inhaled glucocorticosteroid combined with a long-acting β 2-agonist is more effective than the individual components in reducing exacerbations and improving lung function and health status ı(evidence A).
41 Formulations and typical doses of COPD medications Updated GOLD 2010 Drug Inhaler Oral Duration of Action (Hours) ıindacaterol Long Acting ıroflumilast ı (dpi) ı24 ı500 mcg (Pill) ı24 PDE4 Inh.
42 ıpreventive treatment in COPD LABA LAMA ICS
43 Management of Stable COPD Non-Pharmacologic Treatments Rehabilitation: All COPD patients benefit from exercise training programs, improving with respect to both exercise tolerance and symptoms of dyspnea and fatigue (Evidence A). Oxygen Therapy: The long-term administration of oxygen (> 15 hours per day) to patients with chronic respiratory failure has been shown to increase survival (Evidence A). 32
44 Pulmonary Rehabilitation Improve the dyspnea, exercise ability, health status. Minimal effects on PFTs. Multidiscipilinary program. Should be considered for patients with symptomatic COPD. For patients with moderate to severe COPD (FEV1<80%)
45 Maximal Exercise Capacity Walking distance - Endurance capacity Relief of symptoms ( dyspnea and fatigue) Quality of life Utilization of health care resources Mortality?
46 COPD Indications for Hospitalization ATS/ ERS Guidelines Sudden onset of new or severe symptoms Severe or very severe underlying COPD Onset of new physical findings (edema, change in mental status) Failure to respond to initial medical treatment Associated comorbidities Diagnostic uncertainty (pneumonia? PE?) Older age Inadequate home or social support History of poor adherence with treatment
47 ADULT LUNG TRANSPLANTATION( Alpha-1 COPD CF IPF PPH Re-Tx Other* 13% 6% 2% 17% 29% 9% 24% ISHLT 2008
48 ADULT LUNG TRANSPLANTATION 100 HALF-LIFE 18-34: 5.2 Years; 35-49: 5.6 Years; 50-59: 4.7 Years; 60-64: 3.9 Years; 65+: 3.4 Years Survival (%) ISHLT (N= 3,718) (N= 5,687) (N= 7,402) (N= 2,764) 65+ (N= 710) Years Survival comparisons vs : p < vs and vs. 65+ : p < vs , and 65+: p < vs and vs. 65+: p < vs. 65+: p =.0548
49
2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationCourse Handouts & Disclosure
COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationOptimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center
Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center dtaylor@ochsner.org Observations from Yesterday EPIC is epidemic No EMR No Way!!! Accountability/Benchmarking
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationCOPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS
IN THE NAME OF GOD COPD Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS Definition of COPD* COPD is a preventable and treatable chronic lung disease characterized by airflow limitation that is not fully
More informationAmerican Thoracic Society (ATS) Perspective
National Surveillance System for Chronic Lung Disease (CLD): American Thoracic Society (ATS) Perspective Gerard J. Criner, M.D. Chronic Obstructive Pulmonary Disease (COPD) l Definition: Group of chronic
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationChronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationCOPD Update. Muhammad Talha Khan MD. COPD Exacerbations. COPD Clinical Importance. COPD Pathophysiology. Overview/Objectives
Overview/Objectives COPD Update Muhammad Talha Khan MD Pulmonologist St Croix Regional Medical Center, St Croix Falls, WI. Overview of COPD and disease impact Classification of COPD Severity Treatment
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationSydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK. Affiliated with
Sydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK Affiliated with COPD and Comorbidities Norbert Berend Professor Emeritus University of Sydney Head, Respiratory Research The George Institute
More informationCOPD. Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012
COPD Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012 Attitude It is a disease on which a good deal of wholly, unmerited
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationExacerbations of COPD. Dr J Cullen
Exacerbations of COPD Dr J Cullen Definition An AECOPD is a sustained worsening of the patient s clinical condition from their stable state that is beyond their usual day-to-day variation is acute in onset
More informationPathophysiology of COPD 건국대학교의학전문대학원
Pathophysiology of COPD 건국대학교의학전문대학원 내과학교실 유광하 Rate per 100 0,000 population 550 500 450 400 350 300 250 200 150 100 50 0 Heart disease Cancer Stroke 1970 1974 1978 1982 1986 1990 1994 1998 2002 Year of
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationFact. Objectives 1/6/2016. Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD)
Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD) Jin S. Oh, PharmD Larkin Community Hospital January 10, 2016 Fact COPD is the third leading cause of death in the United
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationObjectives. Advances in Managing COPD Patients
4:45 5:30pm Advances in Managing Patients SPEAKER Nicola Hanania, MD, FCCP, FRCP, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Nicola Hanania, MD,
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationDisclosures. Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease May 14, 2016 Orlando, FL COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United States. Alarmingly, COPD recently became
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationCOPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic
COPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic Learning Objectives Know the adverse effects of COPD exacerbations Know mainstays
More informationCOPD as a comorbidity of heart failure in elderly patients
COPD as a comorbidity of heart failure in elderly patients Professor Mitja Lainscak, MD, PhD, FESC, FHFA Departments of Cardiology and Research&Education, General Hospital Celje Faculty of Medicine, University
More informationAn Update in COPD John Hurst PhD FRCP
An Update in COPD John Hurst PhD FRCP Reader in Respiratory Medicine / Honorary Consultant University College London / Royal Free London NHS Foundation Trust j.hurst@ucl.ac.uk What s new in COPD papers
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE DEFINITION Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease characterized by airflow limitation that is usually progressive
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationEpidemiology of COPD Prof. David M. Mannino, M.D.
Epidemiology of COPD David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health College of Public Health University of Kentucky 1 Outline Definitions Severity Progression
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationPrimary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD
Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor
More informationCOPD Management in LTC: Presented By: Jessica Denney RRT
COPD Management in LTC: Presented By: Jessica Denney RRT Sponsored by Z & D Medical Services, Diamond Sponsor Seizing Opportunities to Provide Individualized Treatment and Device Selection for your COPD
More informationManagement of Acute Exacerbations
15 Management of Acute Exacerbations Cenk Kirakli Izmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital Turkey 1. Introduction American Thoracic Society (ATS) and European Respiratory Society
More informationAsthma ASTHMA. Current Strategies for Asthma and COPD
Current Strategies for Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco,
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationLecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)
Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features
More informationClinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene
Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationBode index as a predictor of severity in patients with chronic obstructive pulmonary disease.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 5 Ver. VII (May. 2016), PP 93-100 www.iosrjournals.org Bode index as a predictor of severity
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More information9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR
Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST
More informationUnderstanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR
Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST
More informationUpdate on COPD John Hurst PhD FRCP
Update on COPD John Hurst PhD FRCP Reader / Consultant in Respiratory Medicine UCL / Royal Free London NHS Foundation Trust Director, UCL Royal Free COPD Centre j.hurst@ucl.ac.uk Questions 1. What is the
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX COPD OUTLINE Definition and Overview Pathophysiology Diagnosis and Assessment Therapeutic
More informationFighting for Air, In Emphysema
Fighting for Air, The Mechanism of Shortness of Breath In Emphysema Albert A. Rizzo, MD FCCP FACP Speaker, Nationwide Assembly of the American Lung Association & Section Chief Pulmonary/Critical Care Medicine
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationCOPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases
COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose
More informationUpdate in Pulmonology Update in Medicine and Primary Care November 11, 2017
Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationYou ve come a long way, baby.
COPD Dr Badri Paudel Dept of Medicine GMC/CHRC 4/22/12 badri@gmc 2 You ve come a long way, baby. Wayne McLaren Former Marlboro Man 4/22/12 badri@gmc 3 Age 30 a robust young man Age 51 riding into the sunset
More informationCOPD exacerbation. Chiara Maruggi, PGY2
COPD exacerbation Chiara Maruggi, PGY2 Learning objectives At the end of this lecture students will be able to: 1) Critically assess patients for COPD and design a management plan. 2) Develop a step-wise
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationCOPD AND PALLIATIVE CARE JEAN WATERS FNP-BC SENTARA RMH PALLIATIVE CARE JANUARY 13, 2018
COPD AND PALLIATIVE CARE JEAN WATERS FNP-BC SENTARA RMH PALLIATIVE CARE JANUARY 13, 2018 THOUGHTS TO CONSIDER What is Palliative Care? COPD and impact on Quality of Life. Prognosis and impact of co-morbidities
More informationPulmonary rehabilitation in severe COPD.
Pulmonary rehabilitation in severe COPD daniel.langer@faber.kuleuven.be Content Rehabilitation (how) does it work? How to train the ventilatory limited patient? Chronic Obstructive Pulmonary Disease NHLBI/WHO
More informationUNDERSTANDING COPD MEDIA BACKGROUNDER
UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the
More informationPresenter Disclosure Information
12:45 1:3 pm Improving Outcomes in COPD SPEAKER Michael Campos, MD Presenter Disclosure Information The following relationships exist related to this presentation: Michael Campos, MD: No financial relationships
More informationCHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA
CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA GOLD GINA Chronic Obstructive Pulmonary Disease (COPD) COPD is currently the fourth leading cause of death in the world.1 COPD is projected to
More informationManagement of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures
Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board
More informationManagement of Acute Exacerbations of COPD
MiCMRC Educational Webinar Management of Acute Exacerbations of COPD August 22, 2018 MiCMRC Educational Webinar Management of Acute Exacerbations of COPD Expert Presenter: Catherine A. Meldrum PhD RN MS
More informationPulmonary and Critical Care Year in Review
Pulmonary and Critical Care Year in Review Heath E Latham, MD Assistant Professor University of Kansas Dept of Internal Medicine Division of Pulmonary and Critical Care None Disclosure Lung Cancer Screening
More informationResearch in Real Life
Research in Real Life Study 1: Exploratory study - identifying the benefits of pmdi versus Diskus for delivering fluticasone/salmeterol combination therapy in patients with chronic obstructive pulmonary
More informationCommunity COPD Service Protocol
Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults
More informationWhat s New in the Pulmonary Medicine Literature. 24 March 2017 Boca Raton Florida
What s New in the Pulmonary Medicine Literature MARGARET M JOHNSON, MD ASSOCIATE PROFESSOR OF MEDICINE CHAIR, DIVISION OF PULMONARY MEDICINE JOHNSON.MARGARE T2@MAY O.E DU 24 March 2017 Boca Raton Florida
More informationThe impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease
The impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease Dr. Lo Iek Long Department of Respiratory Medicine C.H.C.S.J. Chronic Obstructive Pulmonary Disease (COPD)
More informationDr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher
Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep
More informationPulmonary Pathophysiology
Pulmonary Pathophysiology 1 Reduction of Pulmonary Function 1. Inadequate blood flow to the lungs hypoperfusion 2. Inadequate air flow to the alveoli - hypoventilation 2 Signs and Symptoms of Pulmonary
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationPulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept.
Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept. Plan Chronic Respiratory Disease Definition Factors Contributing
More informationCOPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017
COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationCourse Materials & Disclosure
Pulmonary Disease: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources & Hospice Education Network Inc. Course Materials & Disclosure Course
More informationResearch in Real Life Evaluation of patients with COPD and CKD who would benefit from aclidinium bromide treatment. Version Date: 15 th October 2013
Research in Real Life Evaluation of patients with COPD and CKD who would benefit from aclidinium bromide treatment. Version Date: 15 th October 2013 Draft protocol Characterising patient groups with chronic
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationBlue, Pink and everything in between: an update on COPD. Tara Lohmann MD FRCPC Division of Respirology University of Calgary
Blue, Pink and everything in between: an update on COPD Tara Lohmann MD FRCPC Division of Respirology University of Calgary Disclosures I have eaten lunches provided by many pharmaceutical companies (GSK,
More information